Wire Stories
Eyevensys Raises $12M in a Series B Plus Funding Round
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#Eyevensys–Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has...